A new vaccination strategy designed to induce antibodies that recognize the apex of the HIV Env protein uses Env trimers displayed on liposomes to increase their density and orient them correctly. This presentation enhanced apex-focused antibody responses in macaques, and the monoclonal antibodies isolated after immunization showed binding modes and structural features resembling human broadly neutralizing antibodies (bNAbs), indicating that the vaccine can steer the antibody response toward this vulnerable site. Read More
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui Health Ltd., the developer of the trispecific antibody. Read More
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the financing are expected to fund operations through milestones that include initial clinical data from the company’s two most advanced programs: LTS-201 for Huntington’s disease and LTS-101 for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
BLR Bio LLC has presented new data highlighting the potential of BLR-200 for the treatment of systemic sclerosis (scleroderma). The company also presented data on its research on CCN proteins as potential noninvasive biomarkers for systemic sclerosis. Read More
Dravet syndrome is a rare, severe, lifelong developmental and epileptic encephalopathy that begins in infancy and is marked by prolonged, often fever-triggered seizures that are difficult to control. It is usually caused by mutations in the SCN1A gene and is associated with developmental delay, cognitive and behavioral impairment, and reduced life expectancy. Read More
Work at Coreterra Therapeutics Inc. has led to the discovery of new thienyl compounds intended for potential use in the treatment of schizophrenia. Read More
Researchers at Epics Therapeutics SA reported preclinical findings on EP-102, a METTL3 inhibitor, in models of pancreatic adenocarcinoma (PDAC). Read More
Vanderbilt University has identified new 1-heteroarylazetidine-3-heteroarylmethylcarboxamide 5-HT2B receptor antagonists reported to be useful for the treatment of myocardial infarction, systemic sclerosis and pulmonary arterial hypertension. Read More
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has patented new crystalline salt forms of poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer. Read More
The MTHFD enzyme family is central to one-carbon metabolism, with MTHFD2 showing cancer-selective overexpression linked to poor prognosis. Emerging data also identify MTHFD1 as a therapeutic vulnerability in select tumors, supporting MTHFD-targeted drug development. Read More
Antibody-drug conjugates (ADCs) comprising an antibody targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug have been described in a Shanghai Pharmaceuticals Holding Co. Ltd. patent and are reported to be potentially useful for the treatment of cancer. Read More
Sanyou Biopharmaceuticals Co. Ltd. has prepared and tested new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to a cytotoxic agent through linker reported to be useful for the treatment of lung and stomach cancer. Read More
Hypersialylation in tumor cells is a potent mechanism of tumor immune evasion, pushing cancer progression by suppressing both innate and adaptive antitumor immunity. Shanghai Henlius Biotech Inc. has developed an engineered human sialidase enzyme fused to an anti-B7-H3 nanobody, named E-688 or HLX-316, that improves tumor desialylation, durability and efficacy both in vitro and in vivo, while maintaining a safe profile. Read More
.webp?t=1670008839 "Acute myeloid leukemia")
